liver
Biotech

Roche becomes MASH player via $3.5B deal for 89bio, ph. 3 drug

Roche dived into the MASH space by agreeing to hand over up to $3.5 billion for 89bio and its phase-3-stage candidate.
James Waldron Sep 18, 2025 5:02am
heroimageepng

Identifying Undervalued Assets to Address Unmet Patient Needs

Sep 15, 2025 8:00am
team layoffs workforce

Pfizer, Arvinas lose interest in commercializing PROTAC drug

Sep 18, 2025 7:35am
reducing people on team

ArsenalBio halves staff amid reorganization efforts

Sep 17, 2025 4:55pm
A stethoscope resting on flag of USA

Massachusetts most impacted by NIH research cuts: Grant Witness

Sep 18, 2025 9:38am
obesity overweight weight loss weigh

QL Biopharm links monthly GLP-1 to incumbent-rivaling efficacy

Sep 18, 2025 7:20am
More News

GE HealthCare considering stake sale in China division: report

Sep 18, 2025 2:30pm

Stryker, Siemens Healthineers team up for stroke-treating robot

Sep 18, 2025 11:30am

Carisma’s lifeline disappears as reverse merger plans break down

Sep 18, 2025 10:40am

Biogen inks $85M Alcyone buyout to acquire drug delivery tech

Sep 18, 2025 10:30am